每年專案
個人檔案
學歷
- 2010 臺北醫學大學藥學系博士
- 2006 University of Sourhern CaliforniaPharmaceutical Sciences 碩士
- 2001 臺北醫學大學藥學系學士
經歷
- 2019.12- 臺北醫學大學生技醫療產業研發博士學程副研究員
- 2019.02- 臺北醫學大學生技醫藥商品化中心副研究員
- 2018.04-2019.01 臺北醫學大學生技醫藥商品化中心助理研究員
- 2016.11-2018.03 臺北醫學大學癌症轉譯研究中心助理研究員
- 2014.08-2016.10 臺北醫學大學轉譯醫學研究中心助理研究員
- 2013.01-2014.07 臺北醫學大學博士後研究員
- 2012.03-2012.10 食品藥物管理局審查員
- 2010.08-2012.02 臺北醫學大學博士後研究員
研究興趣
- 有機合成
指紋
查看啟用 Mei-Jung Lai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 12 類似的個人檔案
網路
國家層面的近期外部共同作業。通過按一下圓點深入探索詳細資料。
專案
研究成果
-
CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition
Singh, A., Chang, T. Y., Kaur, N., Hsu, K. C., Yen, Y., Lin, T. E., Lai, M. J., Lee, S. B. & Liou, J. P., 四月 5 2021, 於: European Journal of Medicinal Chemistry. 215, 113169.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 引文 斯高帕斯（Scopus） -
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Mehndiratta, S., Chen, M. C., Chao, Y. H., Lee, C. H., Liou, J. P., Lai, M. J. & Lee, H. Y., 十二月 2021, 於: Journal of Enzyme Inhibition and Medicinal Chemistry. 36, 1, p. 74-84 11 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma
Nepali, K., Hsu, T. I., Hsieh, C. M., Lo, W. L., Lai, M. J., Hsu, K. C., Lin, T. E., Chuang, J. Y. & Liou, J. P., 五月 5 2021, 於: European Journal of Medicinal Chemistry. 217, 113338.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Corrigendum to “1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma” [Eur. J. Med. Chem. 140 (2017) 84–91](S0223523417306931)(10.1016/j.ejmech.2017.09.011)
Liu, Y. M., HuangFu, W. C., Huang, H. L., Wu, W. C., Chen, Y. L., Yen, Y., Huang, H. L., Nien, C. Y., Lai, M. J., Pan, S. L. & Liou, J. P., 九月 15 2020, 於: European Journal of Medicinal Chemistry. 202, 112633.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., 六月 15 2020, 於: European Journal of Medicinal Chemistry. 196, 112329.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取
資料集
-
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Mehndiratta, S. (Contributor), Chen, M. (Contributor), Chao, Y. (Contributor), Lee, C. (Contributor), Liou, J. (Contributor), Lai, M. (Contributor) & Lee, H. (Contributor), Unknown Publisher, 一月 1 2020
DOI: 10.6084/m9.figshare.13207104.v1, https://tandf.figshare.com/articles/journal_contribution/Effect_of_3-subsitution_of_quinolinehydroxamic_acids_on_selectivity_of_histone_deacetylase_isoforms/13207104/1
資料集: Dataset
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 五月 29 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://doi.org/10.6084%2Fm9.figshare.c.4522856.v1
資料集: Dataset
-
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 五月 29 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
資料集: Dataset
-
Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 五月 29 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
資料集: Dataset
-
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 五月 29 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://springernature.figshare.com/articles/Additional_file_5_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202902/1
資料集: Dataset